EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Design, Synthesis, and Evaluation of Camptothecin-Based Antibody–Drug Conjugates with High Hydrophilicity and Structural Stability

Tingyu Xiong, Jiyu Jin iD, Dongliang Liu iD, Chen Jin

Molecules · 2025

DOI: 10.3390/molecules30071398 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecules, 2025. Verfasst von Tingyu Xiong und 3 weiteren Autor:innen. Beteiligte Einrichtung: College of Chemistry and Chemical Engineering, Donghua University, 2999 North Renmin Road, Shanghai 201620, China. Hauptthemen laut MEDLINE: Camptothecin, Immunoconjugates, Drug Design, Antineoplastic Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In this study, we constructed a linear antibody–drug conjugate (ADC), 7300-LP1003, by coupling the camptothecin derivative 095 to a linker through an ether bond. In vitro enzyme experiments indicated that LP1003 releases 095 through the action of tissue cathepsin B. Therefore, we introduced lysine pairs with different water-soluble substituents to further modify the linker and synthesized side-chain ADCs 7300-LP3004 and 7300-LP2004, modified by polysarcosine and polyethylene glycol, respectively. In vitro experiments showed that, after incubation at 55 °C in phosphate-buffered saline for 48 h, 7300-LP3004 aggregation was 45.24%, which was significantly lower than that of 7300-LP1003 (77.14%). Cell cytotoxicity assays demonstrated that the side-chain ADCs, 7300-LP3004 and 7300-LP2004, exhibited significantly higher activity (IC50 values of 39.74 nM and 32.17 nM, respectively) compared to the linear ADC and 7300-Deruxtecan (IC50 of 186.5 nM and 124.5 nM, respectively). In the subcutaneous model of SHP-77 NOD scid gamma mice, when the ADC dose was 5 mg/kg, 7300-LP3004 showed the highest tumor inhibition rate with a tumor growth inhibition (TGI) of 106.09%, which was superior to that of the positive control 7300-Deruxtecan, which had a TGI of 103.95%. In conclusion, 7300-LP3004 demonstrated strong antitumor activity and high physicochemical stability, highlighting the need for further research and development of ADC drugs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CamptothecinImmunoconjugatesDrug DesignAntineoplastic AgentsAnimalsMiceHumansCell Line, TumorHydrophobic and Hydrophilic InteractionsXenograft Model Antitumor AssaysDrug Stability

Stichwörter der Autor:innen

antibody–drug conjugatespolyethylene glycolpolysarcosinetopoisomerase I inhibitor

Substanzen

CamptothecinImmunoconjugatesAntineoplastic Agents

Autor:innen und Institutionen

  • College of Chemistry and Chemical Engineering, Donghua University, 2999 North Renmin Road, Shanghai 201620, China.
  • Shanghai Tekanbio Pharm-Tech Co., Ltd., Room 4001, Floor 4, Unit 3, Building 8, No. 160, Basheng Road, China (Shanghai) Pilot Free Trade Zone, Shanghai 200120, China.
  • Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, School of Chemistry and Molecular Engineering, East China Normal University, 3663 North Zhongshan Road, Shanghai 200062, China.

ORCID-Profile: Jiyu Jin, Dongliang Liu

Zitieren

APA

Xiong, T., Jin, J., Liu, D., & Jin, C. (2025). Design, Synthesis, and Evaluation of Camptothecin-Based Antibody–Drug Conjugates with High Hydrophilicity and Structural Stability. Molecules. https://doi.org/10.3390/molecules30071398

Vancouver

Xiong T, Jin J, Liu D, Jin C. Design, Synthesis, and Evaluation of Camptothecin-Based Antibody–Drug Conjugates with High Hydrophilicity and Structural Stability. Molecules. 2025. doi:10.3390/molecules30071398

BibTeX
@article{Xiong2025,
  author = {Xiong, Tingyu and Jin, Jiyu and Liu, Dongliang and Jin, Chen},
  title = {Design, Synthesis, and Evaluation of Camptothecin-Based Antibody–Drug Conjugates with High Hydrophilicity and Structural Stability},
  journal = {Molecules},
  year = {2025},
  doi = {10.3390/molecules30071398}
}
Kostenlos starten →